Faculty Bibliography

Importance/UNASSIGNED:To date, the association of psychiatric diagnoses with mortality in patients infected with coronavirus disease 2019 (COVID-19) has not been evaluated. Objective/UNASSIGNED:To assess whether a diagnosis of a schizophrenia spectrum disorder, mood disorder, or anxiety disorder is associated with mortality in patients with COVID-19. Design, Setting, and Participants/UNASSIGNED:This retrospective cohort study assessed 7348 consecutive adult patients for 45 days following laboratory-confirmed COVID-19 between March 3 and May 31, 2020, in a large academic medical system in New York. The final date of follow-up was July 15, 2020. Patients without available medical records before testing were excluded. Exposures/UNASSIGNED:Patients were categorized based on the following International Statistical Classification of Diseases, Tenth Revision, Clinical Modification diagnoses before their testing date: (1) schizophrenia spectrum disorders, (2) mood disorders, and (3) anxiety disorders. Patients with these diagnoses were compared with a reference group without psychiatric disorders. Main Outcomes and Measures/UNASSIGNED:Mortality, defined as death or discharge to hospice within 45 days following a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result. Results/UNASSIGNED:Of the 26 540 patients tested, 7348 tested positive for SARS-CoV-2 (mean [SD] age, 54 [18.6] years; 3891 [53.0%] women). Of eligible patients with positive test results, 75 patients (1.0%) had a history of a schizophrenia spectrum illness, 564 (7.7%) had a history of a mood disorder, and 360 (4.9%) had a history of an anxiety disorder. After adjusting for demographic and medical risk factors, a premorbid diagnosis of a schizophrenia spectrum disorder was significantly associated with mortality (odds ratio [OR], 2.67; 95% CI, 1.48-4.80). Diagnoses of mood disorders (OR, 1.14; 95% CI, 0.87-1.49) and anxiety disorders (OR, 0.96; 95% CI, 0.65-1.41) were not associated with mortality after adjustment. In comparison with other risk factors, a diagnosis of schizophrenia ranked behind only age in strength of an association with mortality. Conclusions and Relevance/UNASSIGNED:In this cohort study of adults with SARS-CoV-2-positive test results in a large New York medical system, adults with a schizophrenia spectrum disorder diagnosis were associated with an increased risk for mortality, but those with mood and anxiety disorders were not associated with a risk of mortality. These results suggest that schizophrenia spectrum disorders may be a risk factor for mortality in patients with COVID-19.

Clinical interactions are initially recorded and documented in free text medical notes. ICD coding is the task of classifying and coding all diagnoses, symptoms and procedures associated with a patient's visit. The process is often manual and extremely time-consuming and expensive for hospitals. In this paper, we propose a machine learning model, BERT-XML, for large scale automated ICD coding from EHR notes, utilizing recently developed unsupervised pretraining that have achieved state of the art performance on a variety of NLP tasks. We train a BERT model from scratch on EHR notes, learning with vocabulary better suited for EHR tasks and thus outperform off-the-shelf models. We adapt the BERT architecture for ICD coding with multi-label attention. While other works focus on small public medical datasets, we have produced the first large scale ICD-10 classification model using millions of EHR notes to predict thousands of unique ICD codes

Artificial intelligence (AI) has made stunning progress in the last decade, made possible largely due to the advances in training deep neural networks with large data sets. Many of these solutions, initially developed for natural images, speech, or text, are now becoming successful in medical imaging. In this article we briefly summarize in an accessible way the current state of the field of AI. Furthermore, we highlight the most promising approaches and describe the current challenges that will need to be solved to enable broad deployment of AI in clinical practice.

The cause of Alzheimer's disease (AD) is poorly understood, so forecasting AD remains a hard task in population health. Failure of clinical trials for AD treatments indicates that AD should be intervened at the earlier, pre-symptomatic stages. Developing an explainable method for predicting AD is critical for providing better treatment targets, better clinical trial recruitment, and better clinical care for the AD patients. In this paper, we present a novel approach for disease (AD) prediction based on Electronic Health Records (EHR) and graph neural network. Our method improves the performance on sparse data which is common in EHR, and obtains state-of-art results in predicting AD 12 to 24 months in advance on real-world EHR data, compared to other baseline results. Our approach also provides an insight into the structural relationship among different diagnosis, Lab values, and procedures from EHR as per graph structures learned by our model